+ +

•  

   

     Western blot analysis of EIF2C3 expression in Human brain lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

The EIF2C3 antibody targets the eukaryotic translation initiation factor 2C3 (EIF2C3), also known as Argonaute 3 (AGO3), a member of the Argonaute protein family. These proteins play critical roles in RNA-mediated gene silencing pathways, including microRNA (miRNA) and small interfering RNA (siRNA) mechanisms. AGO3 is a key component of the RNA-induced silencing complex (RISC), which binds small non-coding RNAs to regulate gene expression post-transcriptionally by mRNA degradation or translational repression. Structurally, EIF2C3 contains conserved PAZ and PIWI domains, facilitating RNA binding and endonuclease activity.

EIF2C3 antibodies are widely used in research to study its expression, localization, and interaction partners in cellular processes such as development, differentiation, and oncogenesis. Dysregulation of Argonaute proteins, including EIF2C3. has been implicated in cancers, neurological disorders, and viral defense mechanisms. These antibodies are essential tools for techniques like Western blotting, immunoprecipitation, and immunofluorescence, enabling insights into RISC assembly and miRNA function. Recent studies also explore its role in germline cell maintenance and transposon silencing. Validation of EIF2C3 antibodies often includes knockout controls to ensure specificity, given the high homology among Argonaute family members. Understanding EIF2C3's molecular mechanisms contributes to therapeutic strategies targeting RNA interference pathways.